We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

171 hedge funds and large institutions have $637M invested in Karyopharm Therapeutics in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 57 increasing their positions, 57 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 24

2% more funds holding

Funds holding: 168 → 171 (+3)

0% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 57

0.41% less ownership

Funds ownership: 5.78% → 5.37% (-0.41%)

34% less call options, than puts

Call options by funds: $2.61M | Put options by funds: $3.95M

36% less capital invested

Capital invested by funds: $987M → $637M (-$351M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
171
Holders Change
+3
Holders Change %
+1.79%
% of All Funds
3%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
28
Increased
57
Reduced
57
Closed
24
Calls
$2.61M
Puts
$3.95M
Net Calls
-$1.34M
Net Calls Change
-$4.58M

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$20.4M
2
JGC
J. Goldman & Co
New York
+$15M
3
Morgan Stanley
Morgan Stanley
New York
+$13.4M
4
CLOS
Compagnie Lombard Odier SCmA
Switzerland
+$11.7M
5
LOAMS
Lombard Odier Asset Management (Switzerland)
Switzerland
+$11.7M

Top Sellers

Rank Fund Capital Flow
1
FCM
Frontier Capital Management
Massachusetts
-$26.8M
2
EA
Emerald Advisers
Pennsylvania
-$25M
3
Millennium Management
Millennium Management
New York
-$24.7M
4
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
-$23.2M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$19.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$7.78M -$24.7M -117,013 -70%
GIM
27
Granahan Investment Management
Massachusetts
$7.26M +$2.64M +12,524 +37%
AAM
28
AMI Asset Management
California
$5.27M +$2.02M +9,588 +40%
T. Rowe Price Associates
29
T. Rowe Price Associates
Maryland
$5.19M -$13.5M -64,263 -66%
Charles Schwab
30
Charles Schwab
California
$4.76M -$208K -988 -3%
Macquarie Group
31
Macquarie Group
Australia
$4.01M -$3.79K -18 -0.1%
JP Morgan Chase
32
JP Morgan Chase
New York
$3.58M +$67K +318 +1%
Citigroup
33
Citigroup
New York
$3.54M +$4.47M +21,232 +1,812%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$3.37M -$129K -614 -3%
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
$3.21M -$1.34M -6,378 -24%
Balyasny Asset Management
36
Balyasny Asset Management
Illinois
$3.06M -$1M -4,755 -20%
Deutsche Bank
37
Deutsche Bank
Germany
$3.04M +$1.67M +7,910 +70%
Barclays
38
Barclays
United Kingdom
$2.89M +$617K +2,928 +19%
Rafferty Asset Management
39
Rafferty Asset Management
New York
$2.85M +$2.97M +14,115 +359%
HWAM
40
Hennion & Walsh Asset Management
New Jersey
$2.81M +$3.75M +17,798 New
BC
41
Birchview Capital
Vermont
$2.42M +$590K +2,800 +22%
Bank of America
42
Bank of America
North Carolina
$2.37M +$823K +3,905 +35%
SSA
43
Schonfeld Strategic Advisors
New York
$1.88M +$2.51M +11,914 New
Allianz Asset Management
44
Allianz Asset Management
Germany
$1.85M -$1.84M -8,755 -43%
JAMH
45
Junson Asset Management (HK)
Hong Kong
$1.57M +$1.24M +5,894 +144%
Dimensional Fund Advisors
46
Dimensional Fund Advisors
Texas
$1.54M – – –
Qube Research & Technologies (QRT)
47
Qube Research & Technologies (QRT)
United Kingdom
$1.54M +$774K +3,674 +60%
UBS Group
48
UBS Group
Switzerland
$1.54M +$1.08M +5,149 +112%
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$1.5M -$186K -882 -8%
PFC
50
Phocas Financial Corp
California
$1.43M -$71K -337 -4%
1
2
3 4 5

KPTI Hedge Fund Activity: Q1 2021 in Review

171 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2021, worth a combined $637M — down 36% from $987M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new KPTI positions and 24 closed out — a net gain of 4 holders — while 57 added to existing stakes and 57 trimmed.

The largest buyer was Two Sigma Investments, adding an estimated $20.4M. The largest seller was Frontier Capital Management, cutting an estimated $26.8M.

  • 171 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2021, up from 168 in Q4 2020.
  • Funds reported $637M of Karyopharm Therapeutics stock for Q1 2021, down 36% quarter-over-quarter.
  • 28 funds opened new Karyopharm Therapeutics positions in Q1 2021 and 24 closed out, a net change of +4 holders.
  • The largest Karyopharm Therapeutics buyer in Q1 2021 was Two Sigma Investments, an estimated $20.4M added.
  • The largest Karyopharm Therapeutics seller in Q1 2021 was Frontier Capital Management, an estimated $26.8M sold.

Based on aggregated 13F filings for Q1 2021.